国产热热热精品,亚洲视频久久】日韩,三级婷婷在线久久,99人妻精品视频,精品九热人人肉肉在线,AV东京热一区二区,91po在线视频观看,久久激情宗合,青青草黄色手机视频

CUHK study to benefit lung cancer patients

Updated: 2011-09-27 06:53

By Fan Feifei(HK Edition)

  Print Mail Large Medium  Small

A study released on Monday by the Chinese University of Hong Kong may mark a significant advance in the treatment of lung cancer.

The study has identified a potential biomarker able to help doctors identify which kinds of lung cancer patients will benefit most from treatment with the pharmaceutical bevacizumab.

The study also established that both high and low doses of bevacizumab are capable of achieving similar outcomes.

Lung cancer is the most common cancer in Hong Kong, and the leading cause of cancer-related deaths.

Bevacizumab effectively attacks the growth of tumor blood vessels.

It was approved as a first-line therapy for advanced lung cancer by the US Food and Drug Administration in 2006.

"Although bevacizumab has become one of the first-line treatments for patients with advanced lung cancer, it is still important to identify the optimal dosage and some certain biomarkers will provide hints," Professor Tony Mok of the university's Department of Clinical Oncology said.

Biomarkers are distinctive biological indicators of a process or condition. Any DNA or protein molecule involved in a biological process can be a potential biomarker, said Mok.

The research, carried out since 2008 by Mok and his team, included studies of 300 patients from different countries, with advanced lung cancer.

The patients were divided into two groups. One group was given bevacizumab in 7.5 mg/kg doses, the other 15 mg/kg. Meanwhile, seven biomarkers - some specific protein closely linked to the inhibition of growth of tumor vessels - were assessed.

The research found that among the seven biomarkers, VEGFA is the most critical biomarker for lung cancer and the patients with low VEGFA levels will benefit most from the bevacizumab treatment.

Professor Tony Mok explained: "VEGFA could serve as a potential biomarker for the identification of suitable patients who may benefit from receiving bevacizumab, and help doctors to tailor treatment regimens after identifying the suitable biomarkers."

The results also indicated that the low dose, at 7.5 mg/kg, has the similar efficacy as 15 mg/kg.

"At present, the bevacizumab treatment is very expensive to common patients and a treatment cycle every three weeks at 7.5 mg/kg costs about HK$15,000 -20,000, and dosages at 15 mg/kg cost around double that," Mok said.

"Thus, the newest finding will save the medical cost for patients since they can achieve the same treatment outcome with half the cost. This significantly improves the cost-effectiveness of treatment," Mok said.

The latest discoveries were unveiled at the 2011 European Multidisciplinary Cancer Congress held in Stockholm, Sweden on Saturday.

fanfeifei@chinadailyhk.com

China Daily

(HK Edition 09/27/2011 page1)

两当县| 河南省| 唐河县| 灌南县| 盐山县| 伽师县| 汝阳县| 鲜城| 县级市| 尉氏县| 宁河县| 靖西县| 当涂县| 嘉黎县| 宣城市| 贵定县| 双辽市| 开阳县| 淳安县| 宜州市| 津南区| 郎溪县| 雷波县| 清河县| 安溪县| 年辖:市辖区| 墨竹工卡县| 博罗县| 西乌| 徐汇区| 宜城市| 锦屏县| 台北市| 开鲁县| 松阳县| 老河口市| 高雄市| 铁岭县| 乐平市| 沂南县| 南雄市|